Subscribe, rate and share on your favorite listening platform

Featured episodes

Paul Biondi discusses his role helping Flagship Pioneering’s bioplatform companies grow and thrive, as well as Pioneering Medicines, a new initiative that harnesses the power of multiple Flagship scientific platforms and technologies to create novel treatments for specialty diseases such as metabolic disorders, cardiovascular, and autoimmune diseases. Paul also talks to us about their partnership with the Cystic Fibrosis Foundation to develop breakthrough treatments for CF.

Kate Haviland, CEO of Blueprint Medicines, talks about how personalized medicine is transforming patient care and the company’s focus on applying precision medicine to cancer and hematologic diseases. She also shares how the current environment informs how she approaches leading a publicly traded biotech and her perspective on partnerships.

Matt Gline is the CEO of Roivant Sciences, a company that delivers innovative medicines and technologies to patients by building Vants – nimble, entrepreneurial biotech and healthcare technology companies. Matt discusses how the current market conditions inform how Roivant operates across its portfolio, how telemedicine emerged as a silver lining from the pandemic, and his thoughts on the current labor market.

Florian Brand and Srinivas Rao are the Co-Founders and CEO & CSO, respectively, of atai Life Sciences, a biopharmaceutical company that leverages a decentralized platform approach to incubate and accelerate the development of highly effective mental health treatments that address the unmet needs of patients, including psychedelics and digital therapeutics. They provide an overview of the neuropsychiatry landscape and the history of psychedelics within mental health.